TH
JAZZ icon

Timber Hill’s Jazz Pharmaceuticals JAZZ Stock Holding History

Timber Hill’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,938
Closed -$415K – 2119
2016
Q2 		$415K Buy
+2,938
New +$433K ﹤0.01% 1661

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Timber Hill's JAZZ Position: Q3 2016 in Review

Timber Hill sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 2,938 shares — an estimated $415K sold.

Timber Hill first reported a position in JAZZ in Q2 2016 and held it in 1 quarter. The position peaked at $415K in Q2 2016. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

  • Timber Hill reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Timber Hill sold 2,938 Jazz Pharmaceuticals shares in Q3 2016, an estimated $415K.
  • Timber Hill first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Timber Hill's Jazz Pharmaceuticals position peaked at $415K in Q2 2016.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Timber Hill's 13F filing for Q3 2016, filed 2 Nov 2016.